BioSpace News Archive

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, February 28, 2023, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2022, and to provide a business update.

Masimo announced the findings of a prospective, double-blinded, randomized controlled study published in Medicine in which Dr. Jin Hee Ahn and colleagues at the Sungkyunkwan University School of Medicine in Seoul, Korea, evaluated the ability of Masimo ORi™ to assist clinicians in guiding supplemental oxygenation during elective laparoscopic gastrectomy surgery.

Theranexus and its partners Beyond Batten Disease Foundation and Cardiff University, announced several presentations at WORLDSymposium 2023, an international scientific event focused on lysosomal diseases.

Medivir AB announced that the company’s new Chief Medical Officer Pia Baumann took up her position.

Nordic Nanovector ASA announces that it will report its results for the second half and full year 2022 on Tuesday, 28 February 2023.

Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that it will release its financial results for fiscal year 2022 and provide a business update on Monday, February 27, 2023.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of clinical data from its broad and advancing cardiovascular pipeline and portfolio at the upcoming American College of Cardiology’s 72nd Annual Scientific Session together with World Heart Federation’s World Congress of Cardiology (ACC.23/WCC) in New Orleans, LA from March 4-6, 2023.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023 at 1:30 pm ET.

Further strong organic growth was reported for the year and quarter. Efforts to build an international marketing and sales organization are starting to pay off.

Sensorion, a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, invites you to attend its R&D Day on Thursday 6 April 2023, at 8 am EDT.